A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Apr 21, 2016

AMGEN ASTELLAS BIOPHARMA AND ASTELLAS INTRODUCE REPATHA® (EVOLOCUMAB) FOR THE TREATMENT OF HIGH CHOLESTEROL

FIrst PCSK9 Inhibitor in Japan

TOKYO (April 21, 2016) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; General Manager and Representative Director: Eiichi Takahashi, “Amgen Astellas”) and Astellas Pharma Inc....

Read more about AMGEN ASTELLAS BIOPHARMA AND ASTELLAS INTRODUCE REPATHA® (EVOLOCUMAB) FOR THE TREATMENT OF HIGH CHOLESTEROL
Apr 18, 2016

Astellas Supports the 2016 Kumamoto Earthquake Relief Efforts

Tokyo, April 18, 2016– Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka, “Astellas”) would like to express our deepest sympathy to the victims of the 2016...

Read more about Astellas Supports the 2016 Kumamoto Earthquake Relief Efforts
Apr 8, 2016

Certain media coverage related to Astellas

Tokyo, April 8, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that certain media coverage related to transfer of business of the...

Read more about Certain media coverage related to Astellas
Apr 7, 2016

CHMP Issues Positive Opinion to Include New Data in European Label for XTANDI® (enzalutamide)

-- TERRAIN Trial Showed Statistically Significant PFS Improvement with Enzalutamide Versus Bicalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer --

Read more about CHMP Issues Positive Opinion to Include New Data in European Label for XTANDI® (enzalutamide)
Apr 1, 2016

Astellas Enters a New Collaborative Research Agreement with AIST to Discover Anti-protozoan Parasite Drugs for the Treatment of Chagas' disease, one of Neglected Tropical Diseases

Tokyo, April 1, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") today announced that it has signed a new collaborative research agreement with the...

Read more about Astellas Enters a New Collaborative Research Agreement with AIST to Discover Anti-protozoan Parasite Drugs for the Treatment of Chagas' disease, one of Neglected Tropical Diseases
Apr 1, 2016

Establishment and Start of Operations of Malaysia Subsidiary and Umbrella Organization Covering South East and South Asia Regions

Read more about Establishment and Start of Operations of Malaysia Subsidiary and Umbrella Organization Covering South East and South Asia Regions
Apr 1, 2016

Astellas and LEO Pharma Close Transaction to Transfer Global Dermatology Business

Read more about Astellas and LEO Pharma Close Transaction to Transfer Global Dermatology Business
Mar 29, 2016

Astellas and Mitsubishi Tanabe Pharma Execute Agreement for Share of Compound Libraries

Tokyo and Osaka, March 29, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) and Mitsubishi Tanabe Pharma Corporation (President and Representative Director:...

Read more about Astellas and Mitsubishi Tanabe Pharma Execute Agreement for Share of Compound Libraries
Mar 25, 2016

Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer

Read more about Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
Mar 22, 2016

POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY EVALUATING ROMOSOZUMAB IN MEN WITH OSTEOPOROSIS

BRIDGE Study Met Primary and All Secondary Endpoints

TOKYO (March 22, 2016) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; General Manager and Representative Director: Eiichi Takahashi, “Amgen Astellas”) and Astellas Pharma Inc....

Read more about POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY EVALUATING ROMOSOZUMAB IN MEN WITH OSTEOPOROSIS
Mar 16, 2016

Astellas Selected as a Nadeshiko Brand Component for Excellence in Providing Opportunities for Women

- First time for a Pharmaceutical Company to be named to both Diversity Management Selection 100 and Nadeshiko Brand -

Read more about Astellas Selected as a Nadeshiko Brand Component for Excellence in Providing Opportunities for Women
Mar 4, 2016

Astellas Announces Personnel Changes

Read more about Astellas Announces Personnel Changes
Mar 2, 2016

Notice of Completion of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Notice of Completion of Acquisition of Own Shares
Mar 1, 2016

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Status of Acquisition of Own Shares
Mar 1, 2016

Astellas Announces Personnel Changes and Organizational Change

Read more about Astellas Announces Personnel Changes and Organizational Change
Mar 1, 2016

Astellas Announces Management Structure Change

Read more about Astellas Announces Management Structure Change
Feb 29, 2016

Astellas Receives Approval for a Supplemental New Drug Application for Kiklin® Capsules, a Treatment for Hyperphosphatemia, in Japan

Read more about Astellas Receives Approval for a Supplemental New Drug Application for Kiklin® Capsules, a Treatment for Hyperphosphatemia, in Japan
Feb 24, 2016

Astellas Submits New Drug Application for Linaclotide, Treatment for Irritable Bowel Syndrome with Constipation, in Japan

Tokyo, February 24, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it submitted a new drug application for a guanylate...

Read more about Astellas Submits New Drug Application for Linaclotide, Treatment for Irritable Bowel Syndrome with Constipation, in Japan
Feb 22, 2016

FDA Accepts For Review Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Metastatic Castration-resistant Prostate Cancer with Data from Head-to-Head Studies of Enzalutamide Versus Bicalutamide

Read more about FDA Accepts For Review Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Metastatic Castration-resistant Prostate Cancer with Data from Head-to-Head Studies of Enzalutamide Versus Bicalutamide
Feb 10, 2016

Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries

Read more about Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries
Feb 10, 2016

Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidaries

Read more about Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidaries
Feb 1, 2016

Astellas and CLINO Announce License Agreement to Develop and Commercialize Gene Therapy to Treat Retinitis Pigmentosa

Tokyo and Miyagi, February 1st, 2016 - Astellas Pharma Inc. (TSE : 4503, President and CEO : Yoshihiko Hatanaka, “Astellas”) and CLINO Corporation (President : Noriaki Satake, “CLINO”)...

Read more about Astellas and CLINO Announce License Agreement to Develop and Commercialize Gene Therapy to Treat Retinitis Pigmentosa
Jan 29, 2016

Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Acquisition of Own Shares
Jan 23, 2016

POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 STUDY OF ROMOSOZUMAB IN OSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

FRAME Study Met All Primary Endpoints by Reducing the Incidence of New Vertebral Fracture Through 12 and 24 Months

Read more about POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 STUDY OF ROMOSOZUMAB IN OSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
Jan 22, 2016

REPATHA® (EVOLOCUMAB) APPROVED AS FIRST PCSK9 INHIBITOR IN JAPAN FOR THE TREATMENT OF HIGH CHOLESTEROL

Important Milestone for Certain Japanese Patients With Uncontrolled LDL Cholesterol

Read more about REPATHA® (EVOLOCUMAB) APPROVED AS FIRST PCSK9 INHIBITOR IN JAPAN FOR THE TREATMENT OF HIGH CHOLESTEROL

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts